RedHill Biopharma Net Income Growth & History (RDHL)

RedHill Biopharma's net income was −$429,000 for fiscal 2025.

View full RedHill Biopharma company overview

RedHill Biopharma annual net income history

RedHill Biopharma annual net income

Fiscal yearPeriod endedNet incomeChangeGrowth
20252025-12-31−$429,000$7.8M
20242024-12-31−$8.3M−$32.2M
20232023-12-31$23.9M$95.6M
20222022-12-31−$71.7M$26.1M
20212021-12-31−$97.7M−$21.6M
20202020-12-31−$76.2M−$33.9M
20192019-12-31−$42.3M−$3.5M
20182018-12-31−$38.8M$6.7M
20172017-12-31−$45.5M−$16.2M
20162016-12-31−$29.4M−$8.3M
20152015-12-31−$21.1M

RedHill Biopharma net income trends

Over the last five fiscal years, RedHill Biopharma's net income increased from −$76.2M to −$429,000, a change of $75.7M. The latest reported quarter, Q2 2022, shows −$11.7M.

About the metric

What net income means

Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.

Calculation and source

SEC-reported net income

TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review RedHill Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about RDHL yet. Start the conversation.

Write the first post